https://www.selleckchem.com/products/LBH-589.html
97% of sensitivity analysis simulations showed an ICER below the cost-effectiveness threshold,Conclusion From the perspective of the analysis, the addition of dapagliflozin to standard treatment is a cost-effective option in patients with heart failure with reduced ejection fraction in Colombia. The incremental cost-effectiveness ratio (ICER) of the intervention compared to standard treatment was USD $5,946 per quality adjusted life year gained. The ICER remained below the cost-effectiveness threshold in sub-group analyses. 97% of sensi
Curtir
Comentario
Compartilhar
